NEW YORK (AP) — U.S. drugmaker Pfizer that it has raised its offer for British rival AstraZeneca for a third time, hiking its stock-and-cash offer by 15 percent to $118.8 billion, or 70.73 billion pounds.

If the deal disclosed Sunday is accepted — and it’s no sure thing, given opposition to date from AstraZeneca and the British government — it would be the richest acquisition ever among drugmakers and the third-biggest deal in any industry, according to figures from research firm Dealogic. It would be Pfizer’s fourth deal worth $60 billion or more since 2000.